Facial Pain Specialist in Palamu
Facial pain — whether the brief, electric shock-like jabs of trigeminal neuralgia or the persistent, dull ache of atypical facial pain — is among the most severe and disabling pains known. Dr. Yuvraj Lahre, DM Neurology (AIIMS), Gold Medalist, provides expert evaluation, precise diagnosis, and effective treatment at Palamu Neuro & Eye Care, Palamu.
When to Worry
- !Facial pain with sensory loss or numbness in the distribution of the trigeminal nerve — this indicates a trigeminal neuropathy (damage to the nerve itself) rather than trigeminal neuralgia (which is a hyperexcitable, irritated nerve with normal function between attacks). Trigeminal neuropathy with progressive sensory loss can be caused by: a cerebellopontine angle tumor (acoustic neuroma/vestibular schwannoma, meningioma), a trigeminal schwannoma, a nasopharyngeal carcinoma with perineural spread along the trigeminal nerve, multiple sclerosis plaque in the trigeminal root entry zone, or connective tissue disease (Sjogren's syndrome, systemic sclerosis, mixed connective tissue disease). MRI brain with contrast is mandatory.
- !Herpes zoster ophthalmicus (HZO) — a vesicular rash in the V1 (ophthalmic) distribution of the trigeminal nerve, especially with vesicles on the tip of the nose (Hutchinson's sign). This indicates involvement of the nasociliary branch of V1 and carries a high risk of ocular complications — keratitis, anterior uveitis, scleritis, acute retinal necrosis, and secondary glaucoma. HZO is an ophthalmological emergency requiring immediate antiviral therapy (oral valacyclovir or famciclovir at high doses, or IV acyclovir for severe or immunocompromised patients) and urgent ophthalmology consultation with Dr. Prabha. Delay in treatment can result in permanent vision loss.
- !Facial pain with ipsilateral headache and Horner's syndrome (ptosis, miosis, anhidrosis — the triad of sympathetic denervation) or carotidynia (tenderness over the carotid artery) — this pattern suggests carotid artery dissection, a potentially life-threatening cause of stroke in young adults. The trigeminal nerve's ophthalmic branch provides sensory innervation to the carotid artery and dura, so carotid pathology is referred as facial and periorbital pain. Diagnosis requires CT angiography or MR angiography of the neck.
- !Facial pain with ipsilateral cranial neuropathies — diplopia (CN III, IV, VI involvement), facial weakness (CN VII), hearing loss (CN VIII), dysphagia (CN IX, X), or tongue deviation (CN XII) — multiple cranial neuropathies raise concern for: cavernous sinus pathology (thrombosis, Tolosa-Hunt syndrome — a steroid-responsive granulomatous inflammation, fungal infection in diabetics — mucormycosis, or tumor infiltration), a cerebellopontine angle tumor, carcinomatous meningitis, or granulomatous disease (sarcoidosis, granulomatosis with polyangiitis). MRI brain with contrast and MR venography (for cavernous sinus thrombosis) are required urgently.
- !Facial pain of sudden, severe onset — 'thunderclap' facial pain or headache — reaching maximum intensity within seconds to 1-2 minutes. This pattern of headache is a red flag for subarachnoid hemorrhage from a ruptured intracranial aneurysm, which can present with referred facial or periorbital pain when the aneurysm is in the posterior communicating or carotid-ophthalmic segment. CT brain without contrast followed by lumbar puncture (if CT is negative but suspicion remains high) and CT angiography are required emergently.
- !Facial pain with fever, unilateral periorbital swelling, proptosis, chemosis (conjunctival swelling), ophthalmoplegia (restricted eye movements), and vision loss in a diabetic or immunocompromised patient — rhinocerebral mucormycosis, an angioinvasive fungal infection (Rhizopus, Mucor, Rhizomucor) that begins in the paranasal sinuses and extends into the orbit and cavernous sinus via the blood vessels. It causes thrombosis and tissue infarction. The hallmark is a black, necrotic eschar on the nasal turbinates or palate. This is one of the most rapidly fatal infections known — mortality exceeds 50% even with treatment. It requires urgent ENT and ophthalmology evaluation, surgical debridement, and IV amphotericin B.
Possible Causes
Classical Trigeminal Neuralgia (Neurovascular Compression)
The most common cause of trigeminal neuralgia in patients over 50 — caused by an aberrant loop of an artery (most commonly the superior cerebellar artery, which normally lies in close proximity to the trigeminal nerve root entry zone at the brainstem) compressing and pulsating against the trigeminal nerve root. This chronic mechanical irritation causes focal demyelination of the nerve at the root entry zone (the transition zone between central oligodendrocyte-derived myelin and peripheral Schwann cell-derived myelin — a zone of inherent vulnerability), leading to ephaptic transmission (cross-talk between adjacent axons) and ectopic generation of pain signals. The characteristic feature is paroxysmal, lancinating, electric shock-like pain triggered by innocuous mechanical stimuli (light touch, wind, chewing) in specific trigger zones — the patient flinches with each attack (hence the term 'tic douloureux'). Between attacks, the patient is pain-free (in classic Type 1 TN), and there is no sensory loss on examination. Carbamazepine provides dramatic initial relief, and MRI with thin-cut FIESTA/CISS sequences through the posterior fossa can often identify the compressing vessel. Microvascular decompression (the Jannetta procedure) is the most definitive long-term treatment.
Secondary Trigeminal Neuralgia (Multiple Sclerosis and Tumors)
Trigeminal neuralgia in a young adult (under 40) or bilateral trigeminal neuralgia is strongly associated with multiple sclerosis — a demyelinating plaque in the trigeminal root entry zone at the pons (the same anatomical location where neurovascular compression occurs in classical TN) causes focal demyelination and ephaptic transmission, producing the identical paroxysmal pain. Up to 2-5% of patients with MS develop TN. Cerebellopontine angle tumors — most commonly vestibular schwannoma (acoustic neuroma, which arises from the vestibular division of CN VIII but can compress CN V as it expands), meningioma, or epidermoid cyst — are a less common but critically important secondary cause, because early diagnosis and surgical removal can be curative and prevent further neurological deterioration. MRI brain with gadolinium contrast is mandatory in all cases of TN, and especially in younger patients, bilateral cases, or cases with trigeminal sensory loss on examination.
Temporomandibular Joint (TMJ) Disorders
TMJ disorders are one of the most common causes of non-neuropathic facial pain. The temporomandibular joint is a synovial joint (with an articular disc) located just anterior to the ear canal, formed by the mandibular condyle and the glenoid fossa of the temporal bone. TMJ disorders encompass: myofascial pain and dysfunction (muscle spasm and tenderness of the masseter, temporalis, and pterygoid muscles from parafunctional habits — bruxism, clenching, gum chewing), internal derangement (anterior disc displacement with reduction — a clicking or popping sensation when opening the mouth — or without reduction — limited mouth opening, 'closed lock'), and degenerative joint disease (osteoarthritis or rheumatoid arthritis of the TMJ). The pain is preauricular, worse with chewing, yawning, and jaw movement, and there is tenderness to palpation over the TMJ and muscles of mastication. Associated features include clicking/popping, crepitus, limited range of motion, and deviation of the jaw on opening. Treatment includes: occlusal splints (bite guards, especially at night), NSAIDs, muscle relaxants, physiotherapy, stress management, and in refractory cases, intra-articular injections or surgical interventions (arthrocentesis, arthroscopy, or open joint surgery).
Post-Herpetic Neuralgia (Trigeminal Herpes Zoster)
After an episode of herpes zoster involving the trigeminal ganglion (Gasserian ganglion), up to 10-20% of patients — particularly those over 60 — develop persistent neuropathic pain (post-herpetic neuralgia, PHN) in the affected dermatome that continues for months to years after the rash has resolved. The pain is constant burning, aching, or throbbing, with superimposed sharp, stabbing, or electric shock-like paroxysms. The affected skin is scarred, hypoesthetic (reduced sensation), or allodynic (pain from a stimulus that normally does not cause pain, such as light touch or clothing). PHN results from varicella-zoster virus-induced destruction of sensory neurons and subsequent central sensitization — the spinal trigeminal nucleus becomes hyperexcitable from the loss of inhibitory interneuron control. Risk factors include: age > 60, severe acute pain during the zoster episode, severe rash, and immunosuppression. Treatment is challenging and multimodal — first-line therapies include gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline), and topical lidocaine 5% patch or capsaicin 8% patch (applied directly to the painful but intact skin for 60 minutes under clinic supervision). The recombinant zoster vaccine (Shingrix) reduces the risk of HZ by 97% in adults aged 50-69 and provides a powerful preventive strategy that Dr. Lahre strongly recommends.
Cluster Headache and Other Trigeminal Autonomic Cephalalgias (TACs)
Cluster headache is not typically considered 'facial pain' by patients but frequently involves severe pain in the orbital, supraorbital, and temporal regions — overlapping significantly with the trigeminal nerve distribution. It is classified as a trigeminal autonomic cephalalgia (TAC) because it involves activation of both the trigeminal nerve (causing pain) and the cranial parasympathetic system (causing ipsilateral autonomic features — lacrimation, conjunctival injection, nasal congestion, rhinorrhea, eyelid edema, ptosis, and miosis). Cluster headache attacks are excruciating — consistently rated as among the most severe pains known — and are characterized by strictly unilateral, severe, sharp, stabbing, or boring pain centered around the eye and temple, lasting 15-180 minutes, occurring with circadian and circannual periodicity (attacks at the same time each day, often waking the patient 1-2 hours after falling asleep, with clusters of daily attacks lasting weeks to months, followed by remission periods of months to years). The patient is restless and agitated (pacing, rocking, pressing on the eye), unlike the migraine patient who seeks quiet and stillness. Acute treatment is with high-flow oxygen (12-15 L/min via non-rebreather mask) or subcutaneous sumatriptan. Transitional and preventive therapy includes verapamil (first-line), lithium, topiramate, and in refractory chronic cluster headache, occipital nerve stimulation or deep brain stimulation. Dr. Lahre distinguishes cluster headache from trigeminal neuralgia by the prominent autonomic features and the duration of attacks.
Which Specialist Should You See?
Severe, shock-like facial pain is often a neurological issue rather than a dental one. Dr. Yuvraj Lahre specializes in diagnosing and treating nerve-related facial pain syndromes, such as Trigeminal Neuralgia, offering advanced medical therapies in Medininagar.
Diagnostic Approach
Diagnosis relies on a detailed history of the pain's character, triggers, and precise location. Dr. Lahre meticulously examines the cranial nerves. An MRI is often required to check if a blood vessel is painfully compressing the trigeminal nerve at the base of the brain.
Experiencing Facial Pain?
Don't ignore your symptoms. Get expert evaluation from Dr. Yuvraj Lahre at Palamu Neuro & Eye Care, Palamu.
Frequently Asked Questions
What is trigeminal neuralgia and how is it diagnosed?
Trigeminal neuralgia (TN), also known as tic douloureux, is defined by the International Headache Society as recurrent, unilateral, brief, electric shock-like pains, abrupt in onset and termination, limited to the distribution of one or more divisions of the trigeminal nerve (V1 — ophthalmic, V2 — maxillary, V3 — mandibular). The pain is triggered by innocuous stimuli — light touch, chewing, talking, brushing teeth, a breeze on the face, or shaving — within specific cutaneous or mucosal 'trigger zones.' It is considered one of the most painful conditions known to medicine. The classic form (Type 1) accounts for 80-90% of cases and is characterized by paroxysmal, lancinating pain without background facial pain between attacks. Type 2 (atypical TN) includes aching, throbbing, or burning background facial pain in addition to the paroxysmal attacks. The hallmark on history is a 'refractory period' — after a triggered attack, there is a period of seconds to minutes during which another attack cannot be triggered. Dr. Yuvraj Lahre diagnoses TN primarily through history — the description is so distinctive that a well-taken history is often all that is needed. MRI brain with thin cuts through the trigeminal nerve (FIESTA/CISS sequences) is performed to evaluate for neurovascular compression (an aberrant artery — most commonly the superior cerebellar artery — compressing the trigeminal nerve root entry zone at the brainstem) and to rule out secondary causes (multiple sclerosis plaque, tumor — especially cerebellopontine angle tumors like acoustic neuroma or meningioma).
What are the medical and surgical treatment options for trigeminal neuralgia?
Dr. Lahre's treatment approach for trigeminal neuralgia follows a stepwise algorithm. First-line medical therapy is carbamazepine (started at 100-200 mg twice daily and titrated upward) — it provides excellent initial pain relief in about 70-80% of patients and its response is so predictable that it can be used as a diagnostic test. The dose is titrated to effect and tolerability, typically to 600-1200 mg/day in divided doses. Oxcarbazepine (a keto-analogue of carbamazepine with fewer drug interactions and side effects) is an excellent alternative, also with Level A evidence. Second-line options include baclofen (a GABA-B agonist), lamotrigine, gabapentin, pregabalin, and phenytoin (now rarely used for maintenance but IV phenytoin or fosphenytoin can abort an acute severe exacerbation). For patients who fail or cannot tolerate medical therapy, Dr. Lahre discusses interventional options: (1) Microvascular decompression (MVD) — the most definitive surgical treatment, involving a posterior fossa craniotomy to separate the compressing vessel from the trigeminal nerve root with a Teflon felt pad. It has the highest rate of long-term pain freedom (about 70% at 10 years) but carries the risks of any posterior fossa surgery. (2) Gamma Knife radiosurgery — non-invasive, focused radiation to the trigeminal nerve root entry zone, causing gradual axonal degeneration. Pain relief is delayed (weeks to months) but about 70-80% achieve significant relief. (3) Percutaneous rhizotomy techniques — balloon compression, glycerol injection, or radiofrequency thermocoagulation of the Gasserian ganglion, performed via a needle through the foramen ovale under fluoroscopy. These provide immediate relief but with a trade-off of facial numbness and a higher recurrence rate. Dr. Lahre discusses the risk-benefit profile of each option and coordinates referral to neurosurgical centers for these procedures.
How does atypical facial pain differ from trigeminal neuralgia?
Atypical facial pain (now classified as Persistent Idiopathic Facial Pain — PIFP) is fundamentally different from trigeminal neuralgia. While TN is characterized by brief, paroxysmal, electric shock-like attacks with clear triggers and pain-free intervals, PIFP is a deep, poorly localized, constant, dull aching or burning pain that does not follow the anatomical distribution of a specific nerve or dermatome and lacks the characteristic triggers of TN. It is often bilateral (TN is almost always unilateral), lasts for much of the day, every day, and does not respond to carbamazepine. It is a diagnosis of exclusion — organic causes (dental, sinus, TMJ, neurological) must first be thoroughly evaluated and ruled out. PIFP overlaps significantly with other chronic pain disorders (fibromyalgia, chronic fatigue, irritable bowel syndrome) and is associated with higher rates of depression and anxiety — though it is important to understand that PIFP is a genuine pain disorder, not 'psychological pain.' Treatment is challenging and focuses on tricyclic antidepressants (amitriptyline, nortriptyline — which are effective for neuropathic pain independent of their antidepressant effect), SNRIs (duloxetine, venlafaxine), gabapentinoids, and a multidisciplinary approach including cognitive behavioral therapy and pain psychology. Dr. Lahre takes a compassionate, non-judgmental approach to PIFP — validating the patient's pain experience while setting realistic treatment expectations.
Can dental problems cause facial pain, and when should a neurologist be consulted?
Dental pathology is one of the most common causes of facial pain. Odontogenic pain (from dental caries, pulpitis, periapical abscess, or periodontal disease) is typically well-localized, throbbing, triggered or worsened by hot/cold/sweet stimuli, and percussion of the affected tooth reproduces the pain. Many patients with trigeminal neuralgia initially consult a dentist because the pain is triggered by chewing or brushing teeth and radiates to the maxilla or mandible — and tragically, some undergo unnecessary dental extractions (even of healthy teeth) before the correct diagnosis is made. Temporomandibular joint (TMJ) disorders cause preauricular pain that worsens with jaw movement, chewing, and yawning, with tenderness over the TMJ and masseter and temporalis muscles, and often associated clicking or locking. Dr. Lahre recommends consulting a neurologist when: (1) facial pain is paroxysmal, electric shock-like, and triggered by light touch or innocuous stimuli (suggesting trigeminal neuralgia), (2) pain is accompanied by sensory loss or numbness in the face — neurological facial pain (trigeminal neuropathy from herpes zoster, compression, or MS) often has demonstrable sensory loss, while dental pain does not, (3) pain does not respond to appropriate dental treatment, (4) pain is associated with neurological symptoms — headache, visual changes, diplopia, dizziness, numbness elsewhere, or weakness, and (5) pain is constant, poorly localized, and has defied multiple dental, ENT, and medical evaluations (suggesting PIFP). At Palamu Neuro & Eye Care, Palamu, Dr. Lahre collaborates with dental and ENT colleagues to ensure comprehensive evaluation.
What is post-herpetic neuralgia and how does it cause facial pain?
Post-herpetic neuralgia (PHN) is the most common complication of herpes zoster (shingles) — a reactivation of the varicella-zoster virus that has remained dormant in the sensory ganglia (the trigeminal ganglion, or Gasserian ganglion, for facial zoster, or the dorsal root ganglia for truncal zoster) since the primary chickenpox infection. When the virus reactivates (triggered by age-related decline in cell-mediated immunity, immunosuppression, or stress), it travels down the sensory nerve, causing the characteristic painful vesicular rash in the dermatomal distribution of the affected nerve. If the ophthalmic division (V1) of the trigeminal nerve is involved, it is called herpes zoster ophthalmicus (HZO) — vesicles on the tip of the nose (Hutchinson's sign) indicate involvement of the nasociliary branch of V1 and are a strong predictor of ocular involvement (keratitis, uveitis, retinitis, acute retinal necrosis — an ophthalmic emergency). PHN is defined as pain persisting for more than 90 days after the rash has healed — it is a neuropathic pain caused by varicella-zoster virus-induced damage to the sensory nerve, leading to spontaneous ectopic discharges, central sensitization, and loss of GABA-ergic inhibitory interneurons in the dorsal horn (or trigeminal nucleus for facial zoster). The pain is constant burning with superimposed lancinating components, and the affected skin is often scarred and hypoesthetic, with allodynia (light touch causes pain). PHN is notoriously difficult to treat once established, making prevention key — the recombinant zoster vaccine (Shingrix), recommended for adults aged 50 and older, reduces the risk of HZ by over 90% and PHN by over 85%. Dr. Lahre manages PHN with gabapentinoids, tricyclic antidepressants, topical lidocaine or capsaicin, and in refractory cases, interventional pain procedures.